Skip to main content
. 2023 Jan 6;18(1):e0280214. doi: 10.1371/journal.pone.0280214

Fig 5. Tumor incidence rate (%) after MNU administration in different dosages.

Fig 5

Tumor incidence in each group (A); the incidence of lung tumor (B); the incidence of adenocarcinoma and TML metastasis in the lungs (C); the incidence of thymic malignant lymphoma (TML) in the lungs; and the incidence of TML metastasis (E). *P < 0.05, **P < 0.01, ***P < 0.001 versus wild-type mice, as assessed using chi-square test.